Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eicosanoyl-5-hydroxytryptamide (EHT) is a naturally occurring bioactive compound found in coffee, structurally described as a serotonin derivative with a C20 saturated fatty acid (eicosanoic acid) linked to the serotonin amino group[1][2][6][9]. EHT exhibits neuroprotective properties and has been investigated as a therapeutic agent, especially for neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease[1][3][5][7][8][9][12]. Its mechanism of action is primarily reported as inhibition of protein phosphatase 2A (PP2A) methylesterase, preserving active PP2A, thereby reducing abnormal phosphorylation and aggregation of α-synuclein and tau proteins—events closely associated with neurodegenerative pathology[3][5][9][12]. EHT has antioxidative effects, upregulates brain-derived neurotrophic factor (BDNF), inhibits acetylcholinesterase activity, and reduces neuroinflammation[1][3]. In animal studies, EHT preserves neuronal structure and function, improves cognitive and motor performance, and acts synergistically with caffeine for neuroprotection[3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eicosanoyl-5-hydroxytryptamide.